Globally, multiple PARP inhibitors (PARPi) have been approved for various cancers, including ovarian, fallopian tube, primary peritoneal, prostate, breast, and pancreatic cancers. In parallel, homologous recombination deficiency (HRD) testing is recognized as a critical predictive biomarker for PARPi efficacy. Current NCCN, ESMO, and CSCO guidelines recommend HRD biomarker testing for ovarian and breast cancers to guide PARP inhibitor therapy decisions. Genecast's proprietary HRD detection solution simultaneously analyzes genomic instability (via LOH, TAI and LST biomarkers), BRCA1/2 mutations and HRR gene alterations, HRR gene alterations, offering a comprehensive method to expand patient eligibility for PARP inhibitors.

To learn more about Genecast HRD, please visit.